Calhoun Vision Inc.
Calhoun Vision Inc. is listed today as RxSight, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Feb 2017 | $50 M | No. 4 | $10 to $50 million | equity | SEC | |
| Oct 2012 | $13 M | No. 3 | $10 to $50 million | equity | SEC | |
| Oct 2011 | $5 M | No. 2 | $2 to $10 million | equity | SEC | |
| Aug 2009 | $9 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company RxSight, Inc., its revenue in fiscal 2025 came from these product and service lines: LAL $108.06 million (80%), L D D $20.67 million (15%), Service Warranty, Service Contracts, And Accessories $5.75 million (4%).
Annual report (SEC XBRL) · Dec 2025
Calhoun Vision Inc. chose not to state its revenue in its newest notice of a funding round (Apr 2017).
SEC Form D · Apr 2017
The industry group it chose in its notices: Other Technology.
SEC Form D · Apr 2017
Products and services#
No products or services of Calhoun Vision Inc. are on record.
Investors#
3 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Daniel Mark Schwartz | Person | not stated | not stated | Held Series C preferred stock, director (Form 3, 2021) | SEC Form 3 |
| Richard M. Wolfen | Person | not stated | not stated | Held Series A, B, D, E, G and H preferred stock, director (Form 3, 2021) | SEC Form 3 |
| RxSight I, LLC | Other | not stated | not stated | Held Series H preferred stock, 10% owner (Form 3, 2021) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 62 investors.
Largest shareholders today
Institutions holding RxSight, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$31 M15.13%
- Millennium Management LLC$10 M5.11%
- D. E. Shaw & Co., Inc.$9 M4.52%
- No Street GP LP$8 M4.05%
- Vanguard Capital Management LLC$8 M4.00%
- Acadian Asset Management LLC$7 M3.46%
- Point72 Asset Management, L.P.$7 M3.42%
- Driehaus Capital Management LLC$6 M2.96%
- Deep Track Capital, LP$6 M2.93%
- Federated Hermes, Inc.$6 M2.90%
- AQR Capital Management LLC$6 M2.80%
- Jacobs Levy Equity Management, Inc$5 M2.54%
- Two Sigma Investments, LP$4 M2.19%
- Geode Capital Management, LLC$4 M2.10%
- State Street Corp$4 M2.03%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Ron Kurtz | Executive officer | Apr 2017 |
| Shelley Thunen | Executive officer | Apr 2017 |
| D. Verne Sharma | Executive officer | Mar 2014 |
| Richard F. Drinkward | Executive officer | Mar 2014 |
| John Maynard | Executive officer | Sep 2009 |
| Bruce Robertson | Director | Apr 2017 |
| Chris Cox | Director | Apr 2017 |
| Dan Schwartz | Director | Apr 2017 |
| J. Andy Corley | Director | Apr 2017 |
| Juliet Bakker | Director | Apr 2017 |
| Ron Kurtz | Director | Apr 2017 |
| Werner Wolfen | Director | Apr 2017 |
| William Link | Director | Apr 2017 |
| D. Verne Sharma | Director | Mar 2014 |
| Daniel M. Schwartz | Director | Mar 2014 |
| James N. Adler | Director | Mar 2014 |
| Jan N. Bonel | Director | Mar 2014 |
| Javier H. Perez-Sala | Director | Mar 2014 |
| Joseph F. Devivo | Director | Mar 2014 |
| Robert H. Grubbs | Director | Mar 2014 |
| Werner F. Wolfen | Director | Mar 2014 |
| Jack H. Kavanaugh | Director | Oct 2011 |
| Jan D. Bonel | Director | Aug 2010 |
| John D. Baxter | Director | Aug 2010 |
| Jack Kavanaugh | Director | Sep 2009 |
| Jan Bonel | Director | Sep 2009 |
| Javier Perez-Sala | Director | Sep 2009 |
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.